Article Details

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies - TradingView

Retrieved on: 2025-03-17 15:04:35

Tags for this article:

Click the tags to see associated articles and topics

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies - TradingView. View article details on hiswai:

Excerpt

EsoBiotec is a biotechnology ... The acquisition will integrate EsoBiotec's proprietary ENaBL platform, which empowers the immune system's ability to ...

Article found on: www.tradingview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo